Mental state: clinically important change in mental state · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functioning: specific ‐ social ‐ clinically important change · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: clinically important adverse effect of intervention ‐ as defined by individual studies · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Leaving the study early Leaving the study early: participants lost to · patients with schizophrenia
1 finding from 1 review
Costs (direct and indirect) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Physical health: clinically important change · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: Clinically important change ‐ no improvement ‐ defined as PANSS < 50% reduction (short term) · patients with schizophrenia
WENDAN DECOCTION may leads to lower global state: Clinically important change ‐ no improvement ‐ defined… compared with PLACEBO OR NO TREATMENT (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
WENDAN DECOCTION probably leads to lower adverse effects: Movement disorders ‐ Extra Pyramidal Symptoms… compared with ANTIPSYCHOTIC DRUG (moderate certainty).
1 finding from 1 review
Adverse effects: Metabolic ‐ weight change (medium term) · patients with schizophrenia
1 finding from 1 review
Quality of life/satisfaction with care: Clinically important change in quality of life/satisfaction, as defined by each study (medium term) · patients with schizophrenia
1 finding from 1 review
Economic outcomes: Costs due to treatment, as defined by each study (long term) · patients with schizophrenia
1 finding from 1 review
Use of Western medicine: Reduced dose of Western medicine (short term) · patients with schizophrenia
1 finding from 1 review
Global state: Clinically important change ‐ no improvement ‐ defined as PANSS < 50% reduction (short term) · patients with schizophrenia
WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC probably leads to lower global state: Clinically important change ‐ no improvement ‐ defined… compared with NORMAL DOSE ANTIPSYCHOTIC (moderate certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC probably leads to lower adverse effects: Movement disorders ‐ Extra Pyramidal Symptoms… compared with NORMAL DOSE ANTIPSYCHOTIC (moderate certainty).
1 finding from 1 review
Adverse effects: Metabolic ‐ weight change (medium term) · patients with schizophrenia
WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC showed no clear difference in adverse effects: Metabolic ‐ weight change (medium term) compared with NORMAL DOSE ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Quality of life/satisfaction with care: Clinically important change in quality of life/satisfaction, as defined by each study (medium term) · patients with schizophrenia
1 finding from 1 review
Mental state: clinically important change in mental state · patients with schizophrenia
1 finding from 1 review
Economic outcomes: Costs due to treatment, as defined by each study (long term) · patients with schizophrenia
1 finding from 1 review